Please login to the form below

Not currently logged in
Email:
Password:

Elocta

This page shows the latest Elocta news and features for those working in and with pharma, biotech and healthcare.

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Guido Oelkers. Sobi’s  haematology franchise  includes Elocta, a recombinant clotting factor VIII therapy for haemophilia A that offers an extended half-life, and Alprolix, a long-lasting recombinant factor IX

Latest news

  • Sobi takes ownership of rare disease drug Gamifant for $518m Sobi takes ownership of rare disease drug Gamifant for $518m

    Sobi’s president and chief executive Guido Oelkers had promised new acquisitions to bolster the firm’s growth, which is being led by its haemophilia treatments, Elocta and Alprolix..

  • Sobi shows strong growth despite haemophilia competition Sobi shows strong growth despite haemophilia competition

    The company markets Elocta, a recombinant clotting factor VIII therapy for haemophilia A that offers an extended half-life, and Alprolix, a long-lasting recombinant factor IX Fc fusion protein for ... Standard factor VIII therapy requires administration

  • Shire claims EU approval for haemophilia A drug Adynovi Shire claims EU approval for haemophilia A drug Adynovi

    The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share. ... It is jostling for market share with other long-acting Factor VIII products for haemophilia A, including Bayer’s Kovaltry and Sobi's Elocta and while Shire

  • Sobi looks to real-world trial to push Elocta take-up Sobi looks to real-world trial to push Elocta take-up

    Sobi (Swedish Orphan Biovitrum) secured approval for Elocta in Europe at the end of 2015 and started rolling it out in EU markets early last year. ... dose, he noted, adding "A-SURE is an important study that aims to evaluate the effectiveness of Elocta

  • Biogen plans spin-out of haemophilia business Biogen plans spin-out of haemophilia business

    The new publicly-traded company has yet to be named but will start operations with two marketed products - Elocta/Eloctate (efmoroctocog alfa) for haemophilia A and Aprolix (eftrenonacog alfa) for haemophilia

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The process is never guaranteed, but we are hoping Elocta will be accessible to patients from 1 July,” he says. ... Compared to normal timelines, the requirements for haemophilia could be quite frustrating, but Neil is sanguine about the need to wait,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics